HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maier Hoehn, M. M. Articles by Elton, R. L. Search for Related Content PubMed PubMed Citation Articles by Maier Hoehn, M. M. Articles by Elton, R. L.

Low dosages of bromocriptine added to levodopa in Parkinson's disease

From Denver, CO, and East Hanover, NJ.

Thirty-six patients with Parkinson's disease, on levodopa, were admitted to a double-blind, parallel, 40-week study of adjunct bromocriptine in dosages increased by 2.5 mg every 4 weeks. A 37% improvement of the mean neurologic deficit score was obtained at the maximal daily dosage of 20 mg. Improvement was greatest in patients with mild disease. The wearing-off effect, off-dose abnormal involuntary movements, and leg pains, associated with levodopa, improved in over 70% of patients at an average dosage of 13 mg. Only 15% of patients had adverse reactions severe enough to necessitate discontinuance of the drug. Abnormalities of mental state were less severe than expected, but two patients had exacerbations of angina pectoris.

Address correspondence and reprint requests to Dr. Hoehn, 3535 Cherry Creek North Drive, Suite 407A, Denver, CO 80209.

Accepted for publication June 4, 1984.

This article has been cited by other articles:

				C. W. Olanow The role of dopamine agonists in the treatment of early Parkinson's disease Neurology, February 1, 2002; 58(90001): S33 - 41. [Abstract] [Full Text]

				C. W. Olanow, R. L. Watts, and W. C. Koller An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment Neurology, June 12, 2001; 56(suppl_5): S1 - S88. [Full Text] [PDF]

				The Multi-Society Task Force on PVS Medical Aspects of the Persistent Vegetative State- First of Two Parts N. Engl. J. Med., May 26, 1994; 330(21): 1499 - 1508. [Abstract] [Full Text]

				R. Gilmore Review Article: The Use of Somatosensory Evoked Potentials in Infants and Children J Child Neurol, January 1, 1989; 4(1): 3 - 19. [Abstract] [PDF]